Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-06-22

Clinical Trial Update: Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alemtuzumab plus peripheral stem cell transplantation in patients with leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Leukemia | Phase 2 | Status: COMPLETED